Search
-
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
(EP-Europace. vol. 22, n° 2, pp. 205-215, 2020)Article de revue -
Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI
(Thérapie. vol. 74, n° 4, pp. 459-468, 2019-09)Article de revue -
Treatment resistant depression incidence and prevalence using the French nationwide claims database
(Pharmacoepidemiology and Drug Safety. vol. 30, n° 2, pp. 169–177, 2021-02)Article de revue -
Benefit-risk of rivaroxaban 20 or 15mg compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation: a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 1014-1014, 2018-08)Article de revue -
Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting
(Clinical Pharmacology and Therapeutics. vol. 103, n° 6, pp. 1038-1046, 2018-06)Article de revue -
Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study
(The American Journal of Medicine. vol. 132, n° 6, pp. 740-748 e7, 2019)Article de revue -
The Reply : Impact of Average Daily and Cumulative Dose of Statins on Mortality Risk Among Healthy Elderly
(The American Journal of Medicine. vol. 132, n° 7, pp. e622, 2019)Article de revue -
Pharmacoepidemiology of statins
(Thérapie. vol. 74, n° 2, pp. 261-269, 2019)Article de revue -
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation
(Stroke. vol. 50, n° 9, pp. 2469-2476, 2019)Article de revueOpen access -
Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database
(Cancer Epidemiology. vol. 69, pp. 101833, 2020)Article de revueOpen access